534 related articles for article (PubMed ID: 10776829)
21. Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells.
Bhatia N; Agarwal C; Agarwal R
Nutr Cancer; 2001; 39(2):292-9. PubMed ID: 11759294
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
23. Small molecule signal transduction inhibitors for the treatment of solid tumors.
Leary A; Johnston SR
Cancer Invest; 2007 Aug; 25(5):347-65. PubMed ID: 17661211
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory action of epiderstatin on EGF-stimulated growth of mouse epidermal. BALB/MK cells without direct effect on protein kinase activities.
Osada H; Kikuchi K; Makishima F; Isono K
Oncol Res; 1994; 6(1):11-7. PubMed ID: 7919547
[TBL] [Abstract][Full Text] [Related]
25. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
26. Bradykinin-induced p42/p44 MAPK phosphorylation and cell proliferation via Src, EGF receptors, and PI3-K/Akt in vascular smooth muscle cells.
Yang CM; Lin MI; Hsieh HL; Sun CC; Ma YH; Hsiao LD
J Cell Physiol; 2005 Jun; 203(3):538-46. PubMed ID: 15573401
[TBL] [Abstract][Full Text] [Related]
27. Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes.
Zeigler ME; Chi Y; Schmidt T; Varani J
J Cell Physiol; 1999 Aug; 180(2):271-84. PubMed ID: 10395297
[TBL] [Abstract][Full Text] [Related]
28. The use of selective pharmacological inhibitors to delineate signal transduction pathways activated during complement receptor-mediated degranulation in chicken heterophils.
Kogut MH; Lowry VK; Farnell M
Int Immunopharmacol; 2003 May; 3(5):693-706. PubMed ID: 12757738
[TBL] [Abstract][Full Text] [Related]
29. Targeting cancer with small-molecular-weight kinase inhibitors.
Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
[TBL] [Abstract][Full Text] [Related]
30. [Signal transduction by protein tyrosine kinases and antitumor agents].
Mao YJ; Li HH; Li JF; Shen JS
Yao Xue Xue Bao; 2008 Apr; 43(4):323-34. PubMed ID: 18664191
[TBL] [Abstract][Full Text] [Related]
31. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
32. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
33. Cell cycle- and swelling-induced activation of a Caenorhabditis elegans ClC channel is mediated by CeGLC-7alpha/beta phosphatases.
Rutledge E; Denton J; Strange K
J Cell Biol; 2002 Aug; 158(3):435-44. PubMed ID: 12163466
[TBL] [Abstract][Full Text] [Related]
34. MHC-I-induced apoptosis in human B-lymphoma cells is dependent on protein tyrosine and serine/threonine kinases.
Pedersen AE; Bregenholt S; Johansen B; Skov S; Claesson MH
Exp Cell Res; 1999 Aug; 251(1):128-34. PubMed ID: 10438578
[TBL] [Abstract][Full Text] [Related]
35. The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer.
Haisa M
J Int Med Res; 2013 Apr; 41(2):253-64. PubMed ID: 23569026
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
38. The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation.
Mainiero F; Murgia C; Wary KK; Curatola AM; Pepe A; Blumemberg M; Westwick JK; Der CJ; Giancotti FG
EMBO J; 1997 May; 16(9):2365-75. PubMed ID: 9171350
[TBL] [Abstract][Full Text] [Related]
39. Protein kinases and phosphatases as therapeutic targets in cancer.
Ventura JJ; Nebreda AR
Clin Transl Oncol; 2006 Mar; 8(3):153-60. PubMed ID: 16648114
[TBL] [Abstract][Full Text] [Related]
40. Role of protein-tyrosine kinase syk in oxidative stress signaling in B cells.
Takano T; Sada K; Yamamura H
Antioxid Redox Signal; 2002 Jun; 4(3):533-41. PubMed ID: 12215221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
